tiprankstipranks
Incyte, Mirati Therapeutics enter INCB99280 clinical trial and supply pact
The Fly

Incyte, Mirati Therapeutics enter INCB99280 clinical trial and supply pact

Incyte (INCY) and Mirati Therapeutics (MRTX) announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte’s small molecule PD-L1 inhibitor, and adagrasib, a KRASG12C selective inhibitor. Under the terms of the agreement, Incyte will initiate and sponsor the Phase 1/1b study of INCB99280 and adagrasib in patients with KRASG12C-mutated solid tumors. Mirati will supply Incyte with adagrasib for the study.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on INCY:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles